Trials Evaluating Bispecific Antibodies in Earlier Therapy Lines Show Promise
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
IMbrave 150: Patient Characteristics
The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.
IMbrave 150: Overview
Medical experts specializing in hepatocellular carcinoma (HCC) provide a detailed analysis of the IMbrave 150 study design.
Moving the Needle Forward in Cancer Rehabilitation
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Linvoseltamab Achieves Deep and Durable Responses in R/R Multiple Myeloma
Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.
Cancer Rehabilitation May Be Appropriate for Every Type of Cancer
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Aggressive Supportive Care Following Novel Agents May Reduce Infection
Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.
Implementing Cancer Rehabilitation to Improve Quality of Life
Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.
Adverse Events and Clinical Pearls on TKI Utilization in CML
Jorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.
Accelerated Phase CML Treatment Practices
The Oncology Brothers and Jorge Cortes, MD, discuss treatment practices for patients with accelerated phase chronic myeloid leukemia.
Treating Patients with CML Following Progression
An expert on chronic myeloid leukemia provides clinical insights on treatment practices following progression.
Treatment Algorithm for Chronic Phase CML
A hematologist-oncologist and the Oncology Brothers outline treatment paradigms for chronic phase CML and discuss patient monitoring practices.
Patient Workup and Risk Stratification
Jorge Cortes, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss patient workup and risk stratification practices in chronic myeloid leukemia (CML).
When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.
Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.
MonumenTAL-1: Long Term Follow up Efficacy
Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.
Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs
Medical experts give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies
Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape
Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.
Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC
Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "IMbrave 150: Patient Characteristics")
